Corrigendum to ‘specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation’ [International Journal of Biochemistry and Cell Biology (2007) 220–226](S1357272506002378)(10.1016/j.biocel.2006.08.005);Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 1, 2007, Pages 220-226

  Crugliano, Telma ^a   Quaresima, Barbara ^a   Gaspari, Marco ^a   Faniello, Maria Concetta ^a   Romeo, Francesco ^a   Baudi, Francesco ^a   Cuda, Giovanni ^a   Costanzo, Francesco ^a   Venuta, Salvatore ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

BRCA1; Breast cancer; FOL1; Proteomics; TD52

Indexed keywords

BRCA1 PROTEIN; COMPLEMENTARY DNA; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; TUMOR PROTEIN; TUMOR PROTEIN D52; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER PATIENT; GENE MUTATION; GENETIC SUSCEPTIBILITY; HELA CELL; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MISSENSE MUTATION; MUTATION; ONCOGENE; PROTEIN EXPRESSION; TUMOR; UPREGULATION;

EID: 33749831572     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2017.03.006     Document Type: Erratum

References (18)

1. Balleine R.L., Fejzo M.S., Sathasivam P., et al. The hD52 (TPD52) gene is a candidate target gene for eventsresulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes Cancer 29 (2000) 48-57
2. Bondarenko P.V., Chelius D., and Shaler T.A. Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry. Analytical Chemistry 74 (2002) 4741-4749
3. Boutros R., Fanayan S., Shehata M., et al. The tumor protein D52 family: Many pieces, many puzzles. Biochemical and Biophysical Research Communications 325 (2004) 1115-1121
4. Campbell I.G., Jones T.A., Foulkes W.D., et al. Folate-binding protein is a marker for ovarian cancer. Cancer Research 51 (1991) 5329-5338
5. Easton D.F., Ford D., and Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium. American Journal of Human Genetics 56 (1995) 265-271
6. Elnakat H., and Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Advanced Drug Delivery Reviews 56 (2004) 1067-1084
7. Fearon E.R. Human cancer syndromes: Clues to the origin and nature of cancer. Science 278 (1997) 1043-1050
8. Garber J.E., and Offit K. Hereditary cancer predisposition syndromes. Journal of Clinical Oncology 23 (2005) 276-292
9. Jhaveri M.S., Rait A.S., Chung K.N., et al. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Molecular Cancer Therapeutics 3 (2004) 1505-1512
10. Li J., Zhang Z., Rosenzweig J., et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clinical Chemistry 48 (2002) 1296-1304
11. Lindor N.M., Greene M.H., and The Mayo Familial Cancer Program. The concise handbook of family cancer syndromes. Journal of the National Cancer Institute 90 (1998) 1039-1071
12. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
13. Pang J.X., Ginanni N., Dongre A.R., et al. Biomarker discovery in urine by proteomics. Journal of Proteome Research 1 (2002) 161-169
14. Quaresima B., Faniello M.C., Baudi F., et al. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo. Oncology Reports 16 (2006) 811-815
15. Quaresima B., Faniello M.C., Baudi F., et al. In vitro analysis of genomic instability triggered by BRCA1 gene missense mutations. Human Mutation 27 (2006) 715
16. Wang R., Xu J., Saramaki O., et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Research 64 (2004) 1589-1594
17. Wang W., Zhou H., Lin H., et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Analytical Chemistry 75 (2003) 4818-4826
18. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (1995) 789-792